INTAS DRHP PDF

admin

Read more about Intas Pharma files draft prospectus for IPO on Business Standard. Drug maker Intas Pharmaceuticals today said it has filed. Intas Pharmaceuticals, has filed its draft red herring prospectus (DRHP) with Securities and Exchange Board of India (SEBI) for an initial public. Intas Pharma DRHP News: Latest and Breaking News on Intas Pharma DRHP. Explore Intas Pharma DRHP profile at Times of India for photos, videos and latest .

Author: Meztilar Nigul
Country: Sierra Leone
Language: English (Spanish)
Genre: Automotive
Published (Last): 20 September 2010
Pages: 256
PDF File Size: 10.70 Mb
ePub File Size: 13.92 Mb
ISBN: 194-9-77939-427-6
Downloads: 46221
Price: Free* [*Free Regsitration Required]
Uploader: Toshakar

Binish Hasmukh Chudgar, Mr. Intas Pharma buys Spanish company’s hospital business. Intas to buy Teva’s UK, Ireland assets for mn pounds.

Intas Pharma files DRHP for IPO

Web Interface Conceived and Powered By: In what could further strengthen its business in European and non-European countries, Ahmedabad based Intas Pharmaceuticals Ltd has acquired hospital business of Combino Pharm in Spain and Portugal for an undisclosed sum. Intas Pharma files for an IPO. The IPO will be made through a public issue of equity shares of face value of Rs.

MCI to probe foreign jaunts by MP doctors. Drugs sold sans regulator’s nod, safety studies. Monday, 31 December Intas Pharma merges group companies, subsidiaries.

  HERPETOFAUNA WORKERS MANUAL PDF

Intas Pharmaceuticals files DRHP for IPO

Hyderabad-based pharma giant Aurobindo snaps up Portuguese co for Rs crore. Please click here to Sign-in or Sign-up. Chandra kicks off divestment plan.

Please fill the all fields. Mon, Dec 31, Updated Sources said the group has started a process to sell drug discovery services company Advinus Therapeutics, drawing interest from private equity funds Kedaara Capital and True North as well as from strategic players, GVK Biosciences and Lambda, a unit of Intas Pharma.

Intas Pharma files draft prospectus for IPO

Subscribe to BioSpectrum India. According to sources, the company has begun the groundwork for the IPO and approached merchant bankers a couple of months ago.

Intas Ingas is a vertically integrated Indian pharmaceutical company with global operations, engaged in the development, manufacture and marketing of pharmaceutical formulation.

Intas Pharma launches first etanercept biosimilar.

Rahul Gandhi listed as ‘non-Hindu’. The promoters of the company are Mr. All rights reserved Disclaimer. Nimish Hasmukhbhai Chudgar, Dr. From around the Web. Sun Pharma in early talks to buy Intas Pharma.

Intas Pharma files for an IPO

Medical Council of India MCI will investigate a complaint against 11 inhas from Madhya Pradesh who are charged with accepting foreign jaunts sponsored by pharmaceutical company. Enquiry Thanks for contacting us! It has also extended its presence into other therapy areas such as gynecology, infertility, arthritis and the respiratory.

  EXPEDITION TO THE DEMONWEB PITS 3.5 PDF

It is currently ranked as the 12th largest pharmaceutical company in the country with a 2.

We will get in touch with you shortly. Intas Pharma eyes hospitals in Europe, US. Drug-maker Intas Pharmaceuticals has merged all its group companies and subsidiaries over concerns about low profits.

At present, domestic companies are marketing their products only in emerging markets, but the largest and most lucrative market for all pharmaceuticals — the US — is the next stop. Visit Our Digital Magazine: New Delhi, May 26 RPG Life Sciences has sold its Gujarat-based biotechnology unit to Intas Pharmaceuticals for Rs 25 crore to focus on core areas of business and improve long-term competitiveness in a rapidly changing market.

Its products are marketed in over 60 countries, either directly, through its subsidiaries or indirectly, through supply, distribution and other arrangements with various leading global pharmaceutical companies. The Ahmedabad-based company is considering licensing agreements drph hospital-based businesses in these markets. ChrysCap backs Curatio in latest pharma bet.

Subscribe US Now